A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms SIGHT
  • Sponsors Bayer
  • Most Recent Events

    • 01 Apr 2015 Primary endpoint 'Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 Last Observation Carried Forward (LOCF)' has been met, according to a Bayer media release.
    • 01 Apr 2015 According to Bayer media release, based on the 28-week results of the SIGHT study, as well as those of the previous VIEW 1(see profile 700238595) and VIEW 2 (see profile 700238599) trial, Bayer HealthCare has submitted an application for marketing authorization of aflibercept solution for injection for the treatment of patients with wet AMD to the China Food and Drug Administration.
    • 01 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top